CLRB NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Cellectar Biosciences Inc · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 2.57 USD
6.6% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -12.4% below the Trend Line and sits at 8.6% of its 52-week range. The latest completed week returned 6.6%, after a -8.5% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 54/100. Near-term considerations: volume confirmation is below normal; earnings are due in 11d.

Setup score 18 out of 100
Latest Close 2.57 USD 31 Jul 2026
1W Return 6.6% latest completed week
4W Return -8.5% short-term follow-through
12W Return -17.1% quarterly tape
Trend Breadth 0.0% 0 of 52 weeks active
Volume Ratio 0.1x vs 13-week average
What is working
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is weak, so confirmation is not yet broad enough.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 6.6% Latest completed week; four-week move -8.5%. Indicator stack 0/58 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. News sentiment 54/100 54 relevant articles in the latest sentiment read. Event risk 11d Next report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -12.4% below the Trend Line and sits at 8.6% of its 52-week range. The latest completed week returned 6.6%, after a -8.5% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.1x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.0512-week average 0.06

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.05Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -8.5% over four weeks, -17.1% over 12 weeks, and -45.6% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W6.6%
4W-8.5%
12W-17.1%
26W-20.2%
52W-45.6%
Active trend streak0 weeks
Active weeks in one year0
Trend breadth0.0%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.39Latest activity-pressure read.
Pressure change7.8%Four-week change in activity pressure.
Leadership-32.51Latest relative-leadership reading.
RS change3.0%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 64% Model confidence 61%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength81/100Blend of value, momentum, and quality. Underlying universe rank 20; rank 1 is best.
Value65/100Relative valuation strength. Underlying universe rank 36; rank 1 is best.
Quality64/100Profitability and accounting quality. Underlying universe rank 37; rank 1 is best.
Momentum66/100Medium-term price momentum. Underlying universe rank 35; rank 1 is best.
Growth66/100Revenue and earnings growth. Underlying universe rank 35; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-142.8%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
2/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-30.1%
Net share repurchases relative to market value.
Shareholder yield
-30.1%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.3x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity13 / 0

13 acquisitions and 0 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment54/100

Weighted news tone is neutral across 54 relevant articles.

12 positive · 38 neutral · 4 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings11dNext report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-60.6%Distance below the 52-week high.
13-week volatility11.7%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher12 of 2614 weeks finished lower.
Best week+25.1%Week of 19 Jun.
Worst week-17.5%Week of 5 Jun.
Latest week+6.6%Week of 31 Jul.

Shape of recent returns

Strong gains8
Modest gains4
Flat weeks0
Modest losses5
Sharp losses9
Recent vol11.7%13-week weekly-return volatility.
Base vol11.9%52-week weekly-return volatility.
Up/down split24/27Count of positive and negative weeks in the 52-week window.
Average skew9.3% / -9.2%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape19/100

Trend, activity pressure, participation, and risk combine to a 19/100 tape read.

 Indicator analysis30/100

Latest 12-week confirmation: trend 0/12, activity pressure 12/12, relative leadership 0/12.

Activity pressure 0.05; No reversal markers Factors69/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 93 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment54/100

Weighted news tone is neutral across 54 relevant articles.

Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026 Insiders13 / 0

13 acquisitions and 0 disposals in the latest 180-day insider tape.

 Earnings11d

Next report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20262.57 USD6.6%2.93 USD38.40 USD0.39-32.51321.8KOff
24 Jul 20262.41 USD-4.0%2.96 USD38.73 USD0.59-37.41141.0KOff
17 Jul 20262.51 USD-11.0%2.97 USD39.08 USD0.63-37.041.1MOff
10 Jul 20262.82 USD0.4%2.97 USD39.46 USD0.67-33.39171.2KOff
3 Jul 20262.81 USD11.5%3.00 USD39.80 USD0.37-33.51725.0KOff
26 Jun 20262.52 USD-9.7%3.03 USD40.15 USD0.15-40.76282.9KOff
19 Jun 20262.79 USD25.1%3.07 USD40.51 USD0.33-39.47867.3KOff
12 Jun 20262.23 USD-13.9%3.07 USD40.85 USD0.42-52.23581.6KOff
5 Jun 20262.59 USD-17.5%3.09 USD41.24 USD0.64-46.50957.4KOff
29 May 20263.14 USD-1.9%3.12 USD41.57 USD0.84-40.85779.9KOff
22 May 20263.20 USD3.6%3.13 USD41.87 USD0.56-39.681.4MOff
15 May 20263.09 USD-0.3%3.15 USD42.15 USD0.31-42.581.4MOff
8 May 20263.10 USD15.2%3.20 USD42.44 USD0.22-43.9758.0MOff
1 May 20262.69 USD-2.5%3.25 USD42.69 USD0.01-50.05111.9KOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.